To assess the role of endogenous DLC1 protein on the three-drug combination in a line that expresses detectable levels under regular growth conditions, we used CRISPR-Cas9 technology to disrupt the DLC1 gene in NSCLC H157 cells. Here, DLC1 is linked to non-small cell lung carcinoma.